The introduction of herbicide and insect resistance as "first-generation engineered crops" offered agronomic benefits in terms of high yield and low pesticide dependency.
Several strategies for overcoming rituximab resistance are currently being evaluated, including manipulation of the immune system, as well as second-generation engineered anti-CD20 antibodies.
Several strategies have been implemented to improve upon the efficacy of rituximab, including radiolabeled anti-CD20 antibodies, second-generation engineered anti-CD20 antibodies with various potential improvements over rituximab, and novel monoclonal antibodies directed against other B-cell antigens.
The second-generation, engineered, self-labeling TMP-tag (Leu28Cys) exploited a proximity-induced Michael addition reactivity between a Cys28 residue engineered on the eDHFR surface near the TMP binding site and a mild electrophile, such as an α, β-unsaturated carbonyl moiety, e.g., the β-carbon of acrylamide, or a sulfonyl group installed on the TMP derivatives.
Marc Goldsmith, a fourth-generation engineer, who has worked on 16 projects in nuclear power which have been canceled, says that many engineers get so frustrated they leave the profession and go into law or finance, and never face a logarithm again.
First generation products containing engineered nanoscale materials are already appearing in the marketplace, while more sophisticated products are being developed in laboratories around the world.
In the last 5 years, the field of cardiac tissue engineering has transitioned from cardiac tissues derived from various animal species to the production of the first generation of human engineered cardiac tissues (hECTs), due to recent advances in human stem cell biology.
The availability of the first cDNA clone of DHV-1 will allow examination of the molecular mechanisms behind DHV-1 virulence and attenuation, which could in turn lead to the production of second-generation, genetically engineered DHV-1 vaccines.
The availability of this cDNA clone will allow examination of the molecular mechanisms behind FMDV virulence and attenuation, which might in turn allow the production of second-generation, genetically engineered FMDV vaccines.
A battery of second generation AAV vectors, engineered through rational and combinatorial approaches to address the aforementioned concerns, are now available.
